{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-016865","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.796447+00:00","generated_at":"2026-05-15T06:08:10.456276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivos Therapeutics FY2025 revenue up 16% to $17.5M; operating loss widens to $19.9M","bullets":["FY2025 revenue $17.5M, +16% YoY from $15.0M; driven by sleep testing services and SCN acquisition.","Operating loss $19.9M vs $11.2M in FY2024; expenses rose to $30.4M on SCN integration costs.","Cash and equivalents $2.0M at Dec. 31, 2025; subsequent financing raised $6.8M in gross proceeds.","Gross margin held at 60%; business pivoting from VIP enrollment to sleep provider acquisitions and alliances.","Management targets achieving cash-flow-positive operations by end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-016865","json":"https://secwatch.observer/filing/0001493152-26-016865.json","markdown":"https://secwatch.observer/filing/0001493152-26-016865.md","text":"https://secwatch.observer/filing/0001493152-26-016865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/0001493152-26-016865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:08:10.456276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fec7f206f378d6bd699bed2bd4a91f3e49c7f490","claim":"Vivos Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $17.5 million.","evidence_excerpt":"Revenue was $17.5 million for the year ended December 31, 2025, compared to $15.0 million for the full year ended December 31, 2024, a year over year increase of 16%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/0001493152-26-016865-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Revenue","value":"$17.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}